The study aimed to evaluate the safety and effectiveness of an investigational drug in relieving moderate to severe migraine attacks.
Hightower Clinical previously participated in a study evaluating an investigational drug for moderate to severe migraine. The goal was to bring faster and more effective relief to patients experiencing acute episodes.
Migraines are intense headaches often accompanied by nausea, sensitivity to light and sound, and vision changes. They can significantly disrupt daily activities and lower the quality of life. Acute migraine treatment is essential for reducing the severity and duration of an attack.
To identify more effective treatment options, Hightower Clinical conducted a study evaluating an investigational drug. The study aimed to assess the safety and efficacy of the drug across multiple dose ranges in patients experiencing moderate to severe migraine episodes.
Not Recruiting
01
Study Name | Protocol Number | Sponsor |
---|---|---|
Acute Migraine | KAL-AGT01-007 | Alnylam |
The study aimed to evaluate the safety and effectiveness of an investigational drug in relieving moderate to severe migraine attacks.
Adults who experienced moderate to severe migraines were enrolled to assess the potential benefits of the study drug.
No, the trial is currently not recruiting new participants.